- Email: [email protected]
METABOLIC ACIDOSIS IS ASSOCIATED WITH HIGH-DOSE INHALED ALBUTEROL THERAPY IN ACUTE SEVERE ASTHMA
October 2009, Vol 136, No. 4_MeetingAbstracts Abstract: Poster Presentations | October 2009
METABOLIC ACIDOSIS IS ASSOCIATED WITH HIGH-DOSE INHALED ALBUTEROL THERAPY IN ACUTE SEVERE ASTHMA Muhammad A. Rishi, MD; Saleha Z. Chaudhry, MD*; Bimi Sidhu, MD; Christina Blot, MD; Fredrick Ramos, MD; Marylou Gaeta, MD; Yaw Amoateng-Adjepong, MD Bridgeport Hospital, Yale School of Medicine, Bridgeport, CT Chest. 2009;136(4_MeetingAbstracts):35S. doi:10.1378/chest.136.4_MeetingAbstracts.35S-a
Abstract PURPOSE: In this study, we test whether there is a dose related relationship between inhaled albuterol therapy and metabolic acidosis. METHODS: Retrospective analysis of historical, demographic and physiologic data of all pediatric patients ( < 18yrs) admitted to pediatric intensive care unit (PICU) with diagnosis of severe acute asthma between Jan 1st 2007 and Dec 31st, 2008. RESULTS: 201 patients with asthma were admitted to the PICU during the study period. 42 patients (median age 7+/−2.67, 76.2 % male) had blood gases done during the admission and were included in the analysis. 30 patients (71.4%) were on high dose ( > 10 mg/h) continuous inhaled albuterol. There was no difference between age, gender, duration of symptoms before presentation, pediatric risk of mortality score between patient on high dose and low dose ( < 10 mg/h) albuterol. Heart rate and respiratory rate was higher in patients on high dose albuterol (159+/−2.1 vs 132+/−4.3, p = 0.04 and 41+/−5.4 vs 32+/−8.6, p = 0.05). 14 patients (33%) developed metabolic acidosis. 13 (43.3 %) of the patients on high dose albuterol compared to 1 (8.3%) of the low dose inhaled albuterol patients developed metabolic acidosis (p = 0.03). CONCLUSION: High dose inhaled albuterol use is associated with metabolic acidosis in patients with severe acute asthma. CLINICAL IMPLICATIONS: Hyperventilation in treated asthma may be a sign of metabolic acidosis which should be treated with a taper of albulerol therapy. DISCLOSURE: Saleha Chaudhry, No Financial Disclosure Information; No Product/Research Disclosure Information Tuesday, November 3, 2009 12:45 PM - 2:00 PM
METABOLIC ACIDOSIS IS ASSOCIATED WITH HIGH-DOSE INHALED ALBUTEROL THERAPY IN ACUTE SEVERE ASTHMA Muhammad A. Rishi, MD; Saleha Z. Chaudhry, MD*; Bimi Sidhu, MD; Christina Blot, MD; Fredrick Ramos, MD; Marylou Gaeta, MD; Yaw Amoateng-Adjepong, MD Bridgeport Hospital, Yale School of Medicine, Bridgeport, CT Chest. 2009;136(4_MeetingAbstracts):35S. doi:10.1378/chest.136.4_MeetingAbstracts.35S-a
Abstract PURPOSE: In this study, we test whether there is a dose related relationship between inhaled albuterol therapy and metabolic acidosis. METHODS: Retrospective analysis of historical, demographic and physiologic data of all pediatric patients ( < 18yrs) admitted to pediatric intensive care unit (PICU) with diagnosis of severe acute asthma between Jan 1st 2007 and Dec 31st, 2008. RESULTS: 201 patients with asthma were admitted to the PICU during the study period. 42 patients (median age 7+/−2.67, 76.2 % male) had blood gases done during the admission and were included in the analysis. 30 patients (71.4%) were on high dose ( > 10 mg/h) continuous inhaled albuterol. There was no difference between age, gender, duration of symptoms before presentation, pediatric risk of mortality score between patient on high dose and low dose ( < 10 mg/h) albuterol. Heart rate and respiratory rate was higher in patients on high dose albuterol (159+/−2.1 vs 132+/−4.3, p = 0.04 and 41+/−5.4 vs 32+/−8.6, p = 0.05). 14 patients (33%) developed metabolic acidosis. 13 (43.3 %) of the patients on high dose albuterol compared to 1 (8.3%) of the low dose inhaled albuterol patients developed metabolic acidosis (p = 0.03). CONCLUSION: High dose inhaled albuterol use is associated with metabolic acidosis in patients with severe acute asthma. CLINICAL IMPLICATIONS: Hyperventilation in treated asthma may be a sign of metabolic acidosis which should be treated with a taper of albulerol therapy. DISCLOSURE: Saleha Chaudhry, No Financial Disclosure Information; No Product/Research Disclosure Information Tuesday, November 3, 2009 12:45 PM - 2:00 PM